FDA Approves Abiraterone for High-Risk Prostate Cancer

February 8, 2018 – The FDA has approved abiraterone acetate in combination with prednisone for patients with metastatic high-risk castration-sensitive prostate cancer, based on findings from the phase III LATITUDE trial. The approval, which was announced by the company developing the therapy, Janssen Biotech, was based on a 38% reduction in the risk of death with the addition of abiraterone acetate and prednisone to ADT compared with ADT alone. After a median … (leggi tutto)